Home

Richard J Rodgers

CIK 1313397 · Interim CEO and President · last filed 2026-06-23

Richard J Rodgers is an Interim CEO and President who has filed 56 SEC Form 4 insider transactions across 7 companies since 2007. The most recent filing, for NVAX, was dated Jun 23, 2026. Current disclosed insider exposure totals $2.1M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$2.14M

Companies

7

Total Filings

56

Lifetime Open-Market Net

$0

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
NVAX Director 47,370 $7.95 $376.6K $0 9 2026-06-23
ARDX Director 439,998 $4.00 $1.76M $0 13 2026-06-18
Opus Genetics, Inc. (OCUP) Delisted Director 343,022 $1.17 $401.3K $0 19 2026-04-22
SGMT Director — $9.06 — $0 1 2023-07-20
Opus Genetics, Inc. (RNN) Delisted Director — — — $0 6 2019-06-07
TESARO, Inc. (TSRO) Delisted Executive VP & CFO 257,141 — — $0 2 2013-03-08
MGI PHARMA INC (MOGN) Delisted Sr. VP & Controller 4,474 — — $0 4 2008-01-24

Recent Filings

56 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-23 NVAX Mixed +18,880 $0 EDGAR
2026-06-18 ARDX Grant (A) +26,455 $0 EDGAR
2026-04-22 Opus Genetics, Inc. (OCUP) Delisted Grant (A) +24,367 $0 EDGAR
2025-10-30 NVAX Exer (M) +3,800 $0 EDGAR
2025-06-24 NVAX Grant (A) — $0 EDGAR
2025-06-23 ARDX Grant (A) +63,019 $0 EDGAR
2025-06-13 NVAX Exer (M) +10,420 $0 EDGAR
2025-05-02 Opus Genetics, Inc. (OCUP) Delisted Grant (A) +79,504 $0 EDGAR
2025-01-17 ARDX Exer (M) +100,000 $55.0K EDGAR
2025-01-02 NVAX Exer (M) +3,800 $0 EDGAR
Showing 1–10 of 56
Page 1 of 6
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.